ALDX Aldeyra Therapeutics Net earnings per share (EPS TTM)

Graphic logo of Aldeyra Therapeutics Inc. (ALDX)

Trailing twelve-month net income per share demonstrates a lack of stable cash flow, as the success of Aldeyra Therapeutics (ALDX) depends on the approval of new drugs. A monopoly status in dry eye treatment will allow the company to exercise pricing power. The integration of AI and robotics into bio-screening accelerates formula development. The value of -0.32 represents the latest metric reading, capturing the business's current financial return.

ALDX Aldeyra Net earnings per share for the last four quarters (07/04/2022 - 11/16/2026)

Aldeyra - analytical breakdowns and key metrics (ALDX)

- share price and expert price forecast:
Fundamental valuation:aldeyra.com (ALDX)
Mass-produced product of Aldeyra Therapeutics Inc.

Amidst the fierce battle for prescriptions in the closed ophthalmology segment dominated by tech giants, the efficiency of Aldeyra Therapeutics (ALDX) marketing investments directly impacts final returns. The current value of -0.32 reflects the total annual net profit divided by the volume of shares outstanding, which allows the rolling per-share profit metric to filter out market noise and determine the asset's real fundamental value.